Access Minutes Here

The Committee reviewed the Hepatitis C Agents class and unaminously approved adding Mavyret to the PDL at preferred status, moving Pegasys, Pegintron, Sovaldi, Technivie, Viekira Pak and Viekira XR to non-preferred status, and adding Vosevi to the PDL at non-preferred status. The Committee recognized the changing landscape within the Hepatitis C Agents class and identfied that the proposed PDL changes ensure access to cost-effective evidence-based treatment options for MA beneficiaries. 


Categories: NewsTreatment